Table 4.

Attenuation of the association between method of detection and disease-free survival after adjusting for clinical variables and CNIs for study cohort aged 50 to 70 (n = 460)

Factors adjusted forHR (95% CI) for screen vs. symptom detectedFreedman statistic, %Freedman statistic, P
None0.65 (0.44–0.98)
Race0.66 (0.43–0.99)00.99
Histology0.66 (0.44–0.99)1.40.99
Tumor subtype0.69 (0.45–1.08)13.30.41
Ki670.69 (0.44–1.09)11.90.55
Hormonal therapy0.67 (0.45–1.01)6.80.80
Nodal status0.72 (0.48–1.09)23.10.14
Chemotherapy0.71 (0.46–1.09)18.80.26
5 CNIs0.72 (0.47–1.1)22.10.16
Nuclear grade0.71 (0.46–1.09)17.40.35
Age at diagnosis0.66 (0.44–0.98)0.40.72
Tumor size0.76 (0.49–1.19)34.90.09
Tumor size + nodal status + age + grade + Ki670.75 (0.44–1.27)31.70.11
Tumor size + nodal status + age + grade + Ki67 + 5 CNIs0.81 (0.47–1.39)50.00.06